First-Line Dara-BorCyD Treatment
PreclinicalSmall molecule
First-Line Dara-BorCyD Treatment is one of 22 small molecule programs targeting Amyloidosis. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
25 competitors in Amyloidosis
#DrugCompanyPhaseTrials
1Soriatane
GSKApproved
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Decadron
AAspen Global Incorporated
Phase 3
Xeljanz
PPrism Pharmaceuticals
Approved
Velcade
SShilpa Grover, MD, MPH
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Venclexta
AbbViePhase 2
Belamaf
GSKPhase 2
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University First Hospital